On the first day of the medical insurance negotiations, the price reduction of the exclusive variety of Chinese medicine started by 30%!

Medicine Network December 15th, December 14th, Beijing city cold wind, xicheng National People's Congress Convention Center gate has already gathered thirty-five groups or in a hurry of medical people.
in the final days of the New Year, a new round of health-care access talks began, just in time for the old saying, "Good play is always behind."
the rules of this year's health care negotiations are the same as last year, with companies twice quoting more than 15 per cent of the expected price to be out," according to business sources involved in the talks.
round of negotiations is composed of five experts from the Health Insurance Bureau, who take three rounds in the morning, middle and evening.
the first four rounds of negotiations, the normal negotiations let the enterprise calm down a little.
", a total of 751 varieties have passed the formal review this year, and it remains to be known how much participation will eventually take place.
But in just three or four days, even if more than half of the varieties are in intense negotiation efforts, and nearly a hundred varieties are needed to complete the negotiations every day, these hurried medics are busy asking what the style of this round of negotiations is.
the end of 2019, representatives of 150 drugs negotiated with negotiators organized by the National Health Insurance Administration, 70 new successful drugs, gave an average drop of 60.7 percent, and some business representatives left the market because the price cuts were too harsh.
it is understood that this year's pressure axis of this "big play" first by the Chinese medicine enterprises to start.
reported that "each enterprise interview about half an hour, there is the company's exclusive variety of about 1/3 of the price reduction to take the lead in the completion of negotiations."
Fact, from past experience, enterprises have enough psychological expectations for price reduction, cut prices or more, who can meet the new year? Who will break the dream in the cold winter? Looking forward to the official revelation.
the exclusive variety of Chinese medicine catch the "life-saving straw"? According to the Medical Economics Daily, this year is the first Chinese medicine, rare disease drugs have started this round of negotiations.
A very important reason is that, compared with the previous four negotiations, this round for the first time refers to the local health insurance catalog situation: before December 31, 2019 into five (including) more than the latest version of the provincial health insurance drug catalog of drugs, can voluntarily declare the national health insurance drug negotiations.
this is a great opportunity for many Chinese medicine companies that rely on the local health-care catalog, or for the last year, to get into the health-care catalog.
, it's not hard to see why today's multiple exclusive Chinese-made drugs have been shortlisted with price cuts of 30% to 40%.
You know, the latest data from the Southern Institute of Pharmaceutical Economics show that the revenue and profits of China's traditional Chinese medicine manufacturing industry fell by more than 5% in the first three quarters of this year, and the revenue and growth of listed Chinese medicine companies were also the largest decline in the seven sub-sectors, at about -6.3%.
profits fell by -13.5%, which puts pressure on many Chinese medicine companies.
of making money by lying down with exclusive varieties, not to mention the beginning of chinese medicine procurement.
In late July, Qinghai Province's centralized procurement network of pharmaceutical and medical supplies released a list of public drug belt procurement bargaining varieties in Qinghai Province and the results of the proposed selection of drug belt procurement in Qinghai Province's public hospitals, thrombosis injections, magpie equal use of large varieties in its column.
, Liaoning also piloted the local version of the Chinese medicine belt procurement.
2019, Top 20, a Chinese medicine product in the terminals of China's public medical institutions, has accumulated sales of 60.2 billion yuan, with sales of the top 20 varieties exceeding 2 billion yuan, according to Mienet data.
the implementation of the purchase of the same amount of medicines, the decline in drug prices will have a significant impact on the production of these Chinese medicine enterprises.
chinese medicine super 300 billion yuan scale of the market or will be with the volume of procurement officially entered the shuffle stage.
health care system, it may be able to re-create its glory.
"Can you be in charge?" If you can't, you can go out and call to communicate.
" negotiation site is not allowed to enter with the telephone, but the key pricing link, will give enterprises a chance to communicate between decision-making levels, there are two Chinese pharmaceutical enterprises exclusive products through the on-site, off-site total, the first to win the entry ticket.
PD-1 came out on the air, and the race was fierce to say how hot the health-care negotiations were, and PD-1 single resistance was naturally the focus of attention.
understood that this time the national talks at home and abroad approved manufacturers did not have a team, neatly joined the negotiations. the first-instance list released by the
National Health Insurance Administration shows that all seven PD-1/L1 products approved for listing but not covered by health insurance in China have passed the formal review, and if these products have passed the expert review and the enterprise confirmed to participate in the negotiations, the competition can be said to be quite fierce.
In particular, Hodgkin's lymphoma, an adaptive disorder, Xinda Bio, Hengrui Pharmaceuticals, Baiji Shenzhou have been approved, it is expected that the competition is certainly extremely fierce, and the overlap of adaptations, will also lower the threshold for negotiations.
that Thyda's Daboshu will cut its price by 63.73 percent in 2019 to cover health insurance, making it the company's main performance pillar for the year.
sales of more than 1 billion yuan in 2019, and sales are expected to exceed 2 billion yuan this year.
this may be the driving force and expectation of all companies to join the talks.
competition is not only reflected in the price, but also has a profound impact on the products that lag behind in research or approval.
2015, K became the first FDA-approved immuno-checkpoint inhibitor to go on sale, and K became the world's top drug sales growth champion.
PD-1 drugs in China have been approved for 8 20 adaptations, "OK" drugs at that time at nearly half the price of the United States into China, the lowest price in the world.
new product competition has changed after the success of the Carelli Pearl monoantigen of Hengrui Pharmaceuticals or has successfully surpassed the K drug.
the first half of 2020 a total of 484 new PD-1 drug clinical trials were first announced, it is expected that its prospects will be very difficult, and later in the price and market share are facing full of survival pressure.
many corporate products have not yet been listed, the end is doomed.
A business representative who will be involved in the negotiations said: "I am afraid that the non-participating countries will be more and more narrow in the future, but the Chinese market is huge, first get tickets means that there is still an opportunity, the company will show the utmost sincerity to go all out."
", however, with the launch of PD-1 drugs, because of the lack of survival data in the country, the lack of access to its incremental cost-effective ratio on drug economics, which is a major difficulty in negotiations.
assuming that multiple varieties have been successfully negotiated this year, marketing capabilities are the next question.
s target drug negotiations have been inconsetiable since the new rules proposed to set access "big limits" as the last natural day of the year for health care negotiations, when new drugs on the market will get "tickets" to health-care negotiations more quickly.
According to officials previously revealed that the time relaxed, the number of innovative drugs, especially the number of new drugs will increase, but in order to ensure that certain benefits will inevitably be higher pricing, so whether to accept health insurance negotiations price is still unknown, the success rate of this year's negotiations is expected to be lower than in previous years.
This year, a total of nine protein kinase inhibitors were included in the 2020 Health Care Form Review List, including barrettinib tablets, dacotinib tablets, methafonate tablets, methafonate fluoromartinib tablets, methyl sulfonate lentatini capsules, Malay acid nerdinib tablets, pyridoxirin tablets and Zebutini capsules.
is also a area of greater concern in the health care negotiations.
, for example, the first-line treatment drug for late-stage liver cancer stars, and this year will once again embark on the road to health care negotiations.
current price in the Chinese market is 16800 yuan / box, 30 capsules per box, 4mg / grain.
this calculation, the cost of treatment for patients more than a thousand yuan a day, ordinary patients simply can not afford. the emergence of
lenvatini, ending a decade of liver cancer patients without a new targeted drug available history, although the previous demand for self-held liver cancer targeted drugs, in the negotiations do not want to let profit eventually lead to failure, it is expected that this time should change strategy, show enough sincerity to participate in the second negotiation.
domestic enterprises or foreign enterprises, have put down the early wait-and-see mentality.
domestic enterprises do not reduce prices, it is difficult to have a foothold, multinational pharmaceutical companies in the face of the huge Chinese market, certainly can not afford to miss the opportunity, even if there are global price system concerns, but also can not afford to have a surprising move? Judging from the final results of the first four rounds of negotiations, the average drop of more than half not only alleviated the burden of medical care for ordinary people, but also greatly expanded drug sales and improved the availability of drugs.
。